PMID- 28118634
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181202
IS  - 2296-5262 (Electronic)
IS  - 2296-5270 (Linking)
VI  - 40
IP  - 1-2
DP  - 2017
TI  - Clinicopathological Features and Therapeutic Responses of Chinese Patients with 
      Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase 
      Rearrangement.
PG  - 27-33
LID - 10.1159/000454715 [doi]
AB  - BACKGROUND: Presence of anaplastic lymphoma kinase (ALK) rearrangement is an 
      indication for crizotinib in the treatment of patients with advanced or 
      metastatic lung adenocarcinoma. Here, we sought to elucidate the association 
      between clinicopathological features and ALK rearrangement status in Chinese 
      patients with advanced lung adenocarcinoma harboring an ALK rearrangement. 
      PATIENTS AND METHODS: ALK rearrangement status was determined using 
      immunohistochemistry (IHC) in tumor tissues from 120 patients with advanced lung 
      adenocarcinoma, and further assessed by fluorescence in situ hybridization (FISH) 
      assay. The associations between ALK rearrangement status and clinicopathological 
      features were analyzed. RESULTS: According to IHC testing, the ALK-positive rate 
      among the advanced lung adenocarcinoma patients was 6.67% (8/120). FISH 
      validation found 5 patients with ALK rearrangement among the 8 IHC-positive 
      cases. No significant difference was observed regarding age, sex, or smoking 
      status between FISH-positive and -negative patients (p > 0.05). None of the 5 
      FISH-positive patients benefited from first-line chemotherapy. CONCLUSION: IHC 
      can be used as a reliable method for ALK rearrangement screening in patients with 
      lung adenocarcinoma, but further FISH validation is imperative. Presence of ALK 
      rearrangement predicts a more aggressive biological behavior of the tumor and 
      might be indicative of poor response to chemotherapy.
CI  - (c) 2017 S. Karger GmbH, Freiburg.
FAU - Lin, Danxia
AU  - Lin D
FAU - Zeng, De
AU  - Zeng D
FAU - Chen, Chen
AU  - Chen C
FAU - Wu, Xiao
AU  - Wu X
FAU - Wang, Miaojun
AU  - Wang M
FAU - Chen, Jiongyu
AU  - Chen J
FAU - Lin, Hui
AU  - Lin H
FAU - Qiu, Xihui
AU  - Qiu X
LA  - eng
PT  - Journal Article
DEP - 20170116
PL  - Switzerland
TA  - Oncol Res Treat
JT  - Oncology research and treatment
JID - 101627692
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
EIN - Oncol Res Treat. 2017;40(3):114. PMID: 28259889
MH  - Adenocarcinoma/*drug therapy/*pathology
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - China
MH  - Crizotinib
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*drug therapy/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Pyrazoles/therapeutic use
MH  - Pyridines/therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/genetics/*metabolism
MH  - Risk Factors
MH  - Young Adult
EDAT- 2017/01/25 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/01/25 06:00
PHST- 2016/07/21 00:00 [received]
PHST- 2016/11/22 00:00 [accepted]
PHST- 2017/01/25 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/01/25 06:00 [entrez]
AID - 000454715 [pii]
AID - 10.1159/000454715 [doi]
PST - ppublish
SO  - Oncol Res Treat. 2017;40(1-2):27-33. doi: 10.1159/000454715. Epub 2017 Jan 16.